Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Indonesia
  Ireland
  Israel
  Italy
  Jamaica
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malaysia
  Malta
  Mexico
  Montenegro
  Morocco
  Mozambique
  Namibia
  Netherlands
  New Zealand
  Nigeria
  Norway
  Panama
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Sri Lanka
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Thailand
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States
  Vietnam


   Infocentre

Last Update: 04-07-2011  
Related category(ies):
Health & life sciences

 

Add to PDF "basket"

Plaques and the fight against heart disease

Researchers in Europe have discovered that stabilising vulnerable plaques as part of secondary prevention could contribute to eliminating at least 50 % of coronary events. Published in the journal Thrombosis and Haemostasis, the position paper of the European Society of Cardiology (ESC) Working Group of Atherosclerosis and Vascular Biology suggests that research on the causes of plaque rupture, as well as the on development of improved diagnostics and treatments, should be intensified.

Platelets © Shutterstock
Platelets
©  Shutterstock

The position paper tackled the current state of knowledge concerning unstable plaques by investigating the role of inflammation, growth factors, platelets, chemokines, angiogenesis and smoking. Therapies including statins, antiplatelet and antihypertensive treatments were outlined in the paper, and the researchers assessed novel approaches to dealing with cardiovascular events. They also worked on identifying unstable plaques through genetic testing, biomarkers and imaging.

'We want more medical professionals to understand the concept that stabilising vulnerable plaques offers a fundamental approach to preventing cardiovascular events,' explains Seppo Ylä-Herttuala of the University of Eastern Finland in Kuopio, chairman of the position paper task force and lead author. Professor Ylä-Herttuala goes on to say that researchers have observed a drop in cardiovascular events during a number of statin trials for secondary prevention. Such events have also benefited from platelet therapies.

For his part, Dr Christian Weber of Ludwig-Maximilians-University Munich in Germany, a member of the working group, says: 'Widespread stabilisation of vulnerable plaques would also have important socioeconomic implications, dramatically reducing the need for invasive treatments.'

Experts say not all plaques are made equally; some plaques are strong and have the capacity to withstand coronary events while others are more vulnerable and have a tendency to rupture and trigger such events. The researchers point out that these plaques are not necessarily the same as those that cause symptoms such as angina.

Dr Weber says the theory behind vulnerable plaques is that inflammatory cells that emerge from ongoing inflammation destabilise the structure of the plaque. 'It is believed that they degrade the fibres that make the plaque stable, leading to a greater potential for the plaque to rupture,' the German researcher says.

Researchers began investigating plaque stabilisation to describe how the number of acute coronary events could drop when lipids are decreased, without the accompanying regression of coronary atherosclerosis seen using angiography.

The working paper, says Professor Ylä-Herttuala, could help guide general clinicians better. 'The whole field can be really confusing,' he remarks. 'After patients have been treated with statins for two or three years, family doctors can be really concerned that they see no changes on angiograms. In such cases, there's a danger that they may decide to stop life saving treatment,' he adds.

'The single most important advance that would help us to tackle vulnerable plaques would be to have a non-invasive imaging tool that would allow us to identify at risk patients before they suffer an event,' the Finnish researcher says.

As for what the future holds, the position paper suggests more translational research into biomarkers and imaging be carried out, and new treatments be developed.

Says Dr Weber: 'There is a real need to develop treatments specifically for the purpose of stabilising vulnerable plaques. At the moment, we only have treatments that were discovered to have a beneficial effect through serendipity.'

Experts from Denmark, the Netherlands, Poland, Turkey and the United Kingdom also contributed to this paper.


Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

European Society of Cardiology (ESC)
Thrombosis and Haemostasis
'Omega-3 and blood-thinning drugs impact clotting process'





  Top   Research Information Center